# PT-141 for Men: What the Research Shows **By TelosRX Editorial Team** ยท 2026-08-14 **Use of the PT-141 peptide for men is off-label. Bremelanotide is FDA-approved only for premenopausal women, so male use rests on phase 2 research and clinical judgment. Here is what the evidence shows, and what [PT-141 at Telos Rx](https://www.telosrx.com/pages/pt-141) involves.** That is the honest starting point, and it matters more than any claim a marketing page could make. Men searching for bremelanotide deserve to know exactly where the science stops and where a prescriber's judgment begins. This article covers the male research specifically. For the underlying pharmacology, see [what PT-141 is and how bremelanotide works](https://www.telosrx.com/blogs/peptides/what-is-pt-141-bremelanotide-guide). ## Off-Label Means Something Specific In 2019 the FDA approved Vyleesi, a 1.75 mg subcutaneous bremelanotide autoinjector, for acquired, generalized hypoactive sexual desire disorder in premenopausal women. That is the only approved indication for the molecule, anywhere on the label. **There is no FDA-approved bremelanotide product for men.** Prescribing it to a man is an off-label decision, which is legal and common across medicine, but it means the prescriber is working from published research and individual assessment rather than an approved indication. Compounded PT-141 sits a step further out. It is not FDA-approved, and it is prepared by licensed US compounding pharmacies under federal compounding regulations. Any use is subject to medical approval by a licensed provider. ## Why a Centrally Acting Agent Interests Men at All Most drugs men are offered for sexual function work on plumbing. PDE5 inhibitors block an enzyme in vascular smooth muscle, which improves blood flow into the penis, and they require sexual stimulation and an intact nitric oxide pathway to do anything at all. Bremelanotide works somewhere else entirely. It is a melanocortin receptor agonist that acts at MC3R and MC4R receptors in the hypothalamus, in the central nervous system, upstream of any vascular signal. Because the mechanism is central, it does not strictly require sexual stimulation to initiate a response. That distinction is the whole reason men look at it. A man whose erections are mechanically fine but whose interest has flattened is describing a desire problem, not a blood-flow problem, and a vasodilator does not address the part that has gone quiet. For a fuller side-by-side, see [how PT-141 differs from Viagra and Cialis](https://www.telosrx.com/blogs/peptides/pt-141-vs-viagra-cialis). ## What the Phase 2 Research in Men Actually Showed The male evidence base is early-phase, and it is worth being precise about what it contains. A [double-blind, placebo-controlled evaluation of intranasal PT-141](https://pubmed.ncbi.nlm.nih.gov/14963471/) in healthy males and men with mild-to-moderate erectile dysfunction reported dose-dependent pharmacokinetics and a dose-dependent erectile response, with onset of first erection at around 30 minutes. Later reporting on the male program described effects in roughly the 30 to 60 minute range. Those studies were phase 2: relatively small, designed to establish signal and safety rather than to prove clinical benefit at scale. **There is no phase 3 program in men.** The phase 3 work, the two RECONNECT trials, enrolled premenopausal women with acquired, generalized HSDD, and the [published RECONNECT data](https://pmc.ncbi.nlm.nih.gov/articles/PMC8788464/) is what supported approval in that population. Extending it to men is an inference, not a finding. ## Why the Intranasal Route Was Not Carried Forward Much of the early male work used a nasal spray, which is why old forum threads still talk about intranasal bremelanotide. That route was not advanced to FDA approval, because of blood pressure findings associated with it. The subcutaneous route is the one that carried through to approval, and it is the form relevant to current compounding practice. Anyone comparing formats should read [PT-141 nasal spray versus injection](https://www.telosrx.com/blogs/peptides/pt-141-nasal-spray-vs-injection) before assuming the two are interchangeable. ## The Evidence, Question by Question What men ask What the research base supports Is it FDA-approved for me? No. The only FDA-approved indication for bremelanotide is acquired, generalized HSDD in premenopausal women. Male use is off-label. Has it been studied in men? Yes, in phase 2. Studies in men, including men with erectile dysfunction, reported a dose-dependent erectile response with onset in roughly the 30 to 60 minute range. Is there phase 3 evidence in men? No. The phase 3 RECONNECT trials enrolled premenopausal women, not men. Which route reached approval? Subcutaneous. The intranasal formulation studied earlier was not advanced, because of blood pressure findings tied to that route. Does it work on blood flow? No. It acts at MC3R and MC4R receptors in the hypothalamus, upstream of the vascular pathway PDE5 inhibitors target. Is compounded PT-141 FDA-approved? No. It is prepared by licensed US compounding pharmacies under federal compounding regulations. If a desire-first mechanism sounds closer to your situation than another blood-flow drug, the next step is a provider reviewing your history and deciding whether PT-141 is appropriate at all. [See PT-141 at Telos Rx](https://www.telosrx.com/pages/pt-141) ## What Provider Evaluation Involves Because male use is off-label, the evaluation carries more weight than it would for an approved indication. A licensed provider is deciding whether the published research reasonably applies to you, not filling a pre-approved box. Expect questions that separate desire from mechanics: whether interest declined or performance did, whether the change was gradual or situational, what else changed at the same time. Sleep, alcohol, stress, relationship context, testosterone status, antidepressants and other medications all sit in that conversation. Cardiovascular history is the hard gate. Trials excluded people with uncontrolled hypertension or known cardiovascular disease, and bremelanotide is not for people in those categories. A provider will also weigh whether a PDE5 inhibitor has been tried, and what happened. Nothing here is a dose recommendation. What the label specifies for the approved population is documented in our [PT-141 dosage guide](https://www.telosrx.com/blogs/peptides/pt-141-dosage-guide), and any protocol for an individual is set by the prescribing provider. ## Side Effects Reported in Trials The safety picture comes largely from the female phase 3 data, which is the largest controlled dataset available for this molecule. The [NIH LiverTox monograph on bremelanotide](https://www.ncbi.nlm.nih.gov/books/NBK573221/) summarises the label profile. - **Nausea** was the most common adverse effect, reported in roughly 40 percent of trial participants and usually transient. - **Flushing** and **headache** were also frequently reported. - **Injection-site reactions** occurred with subcutaneous administration. - **Transient blood pressure increases** with a modest decrease in heart rate were observed after dosing. - **Focal hyperpigmentation** has been reported with repeated dosing. Bremelanotide belongs to the melanocortin peptide family, which is where the hyperpigmentation signal comes from. It is not a tanning product and should not be treated as one. Our full breakdown of [PT-141 side effects and what trials reported](https://www.telosrx.com/blogs/peptides/pt-141-side-effects-safety) goes through the safety picture in detail. ## How Telos Rx Handles It Telos Rx offers compounded PT-141 as an as-needed subcutaneous dose, taken ahead of anticipated intimacy rather than daily. Compounded PT-141 is not FDA-approved. The service is online-first and asynchronous. You complete an intake, a licensed provider reviews it on their own schedule, and there is no appointment to sit through. It is available in all 50 states, and formulations may vary by state. Approval is not guaranteed. If you want the broader case for the molecule before deciding, our summary of [research-backed benefits of PT-141](https://www.telosrx.com/blogs/peptides/pt-141-bremelanotide-benefits-research-guide) covers the wider evidence base. ## Frequently Asked Questions ### Is PT-141 FDA-approved for men? No. Bremelanotide is FDA-approved only as Vyleesi, for acquired, generalized hypoactive sexual desire disorder in premenopausal women. There is no approved bremelanotide product for men, so any male use is off-label. Compounded PT-141 is separately not FDA-approved and is prepared by licensed US compounding pharmacies under federal compounding regulations. ### What did the research on PT-141 for erectile dysfunction find? Phase 2 studies in men, including men with erectile dysfunction, reported a dose-dependent erectile response, with effects described in roughly the 30 to 60 minute range. These were early-phase studies designed to establish signal and safety. No phase 3 program was completed in men, so the male evidence base remains preliminary rather than confirmatory. ### How long does bremelanotide take to work in men? Published male studies reported onset of erectile response at around 30 minutes, with effects described across roughly a 30 to 60 minute window. For the approved female indication, the label specifies dosing about 45 minutes before anticipated sexual activity. Individual timing varies, and any protocol is determined by the prescribing provider. ### Is PT-141 better than Viagra? They are not competing versions of the same thing. PDE5 inhibitors act on blood flow and require sexual stimulation. PT-141 acts centrally at melanocortin receptors and does not strictly require stimulation to initiate a response. Which one a provider considers depends on whether the issue is desire, mechanics, or both. ### Who should not use PT-141? Clinical trials excluded people with uncontrolled hypertension or known cardiovascular disease, and bremelanotide is not for people in those categories. Transient blood pressure increases were observed after dosing. A full health history, including medications and cardiovascular status, is reviewed by a licensed provider before anything is prescribed. ### Can men get PT-141 through telehealth? Telos Rx reviews requests through an online-first, asynchronous process, with no scheduled appointment required. You complete an intake and a licensed provider evaluates it. Approval is subject to evaluation by a licensed provider and is not guaranteed. The service is available in all 50 states, and formulations may vary by state. _TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service._ If the desire side is what has changed for you, read the full product details on [the PT-141 page at Telos Rx](https://www.telosrx.com/pages/pt-141), then [start your online visit for men](https://start.telosrx.com/start-online-visit/pt141men). A licensed provider reviews every request asynchronously, and approval is not guaranteed. **Tags:** bremelanotide, erectile dysfunction, mens health, off-label, peptides, PT-141, sexual health, telehealth --- > Source: [Telos RX](https://www.telosrx.com/blogs/peptides/pt-141-for-men-research-guide)